Brief: Ascletis Pharma Says 3Clpro Inhibitor ASC11 Demonstrated Potential To Be Effective Treatment For COVID-19
19/04/2022 11:03
April 19 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS PHARMA INC - 3CLPRO INHIBITOR ASC11 DEMONSTRATED
POTENTIAL TO BE EFFECTIVE TREATMENT FOR COVID-19
* ASCLETIS PHARMA INC - EXPECTED THAT IND OF ASC11 WILL BE
FILED
IN SECOND HALF OF 2022
* ASCLETIS PHARMA - PHASE I CLINICAL TRIAL IN HEALTHY
SUBJECTS
WILL BE COMPLETED BY END OF 2022
Source text for Eikon: ID:
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management